Korro Bio Inc
Research Korro Bio Inc (KRRO) on Bullrun: market cap USD 201.91M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerKRRO
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 201.91M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 18.92M
- Free cash flow-USD 17.03M
Valuation Snapshot
latest market cap is USD 201.91M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 6.39M | -USD 117.26M | -USD 79.08M | n/a | -12.48 | USD 21.82M | USD 43.49M | USD 51.44M |
| FY2024 | USD 2.27M | -USD 83.58M | -USD 77.98M | n/a | -9.37 | USD 55.64M | USD 44.77M | USD 160.42M |
| FY2023 | USD 0 | -USD 81.17M | -USD 75.12M | n/a | -53.08 | USD 166.15M | USD 33.21M | USD 169.91M |
| FY2022 | USD 0 | -USD 58.03M | -USD 58.78M | n/a | -227.42 | USD 36.33M | USD 10.00M | -USD 99.03M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 201.91M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 75.43M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 356.99M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 383.99M | n/a | n/a | n/a |
About Korro Bio Inc
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Korro Bio Inc's market cap?
Korro Bio Inc's market capitalization is USD 201.91M.
What does Korro Bio Inc do?
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates.